# Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

> **NCT06519526** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 25 (estimated)

## Conditions studied

- Relapsed/Refractory Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** SHR-0302
- **DRUG:** SHR-2554

## Key facts

- **NCT ID:** NCT06519526
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-08-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519526, "Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06519526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*